Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Operating Cash Flow

Cash generated by the company's core business operations during the period.

Vicore Pharma Holding ABNASDAQ: VCRE

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow declines year over year

Q2 FY2026 operating cash flow of SEK 16.08M (cash outflow) fell 84.9% year over year, behind the -31.6% change in trailing-twelve-month operating cash flow. Sequentially, it fell 86.3% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.

Context

  • Operating cash flow amounted to 9843.8% of revenue in FY2025, up 9692.9 pp from a year earlier.
  • Operating cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -84.9% toward the trailing-twelve-month pace of -31.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-SEK 16.08M-86.3% QoQ
Last fiscal yearDec 2025
-SEK 375.74M+127.8% YoY
LTMJun 2026
-SEK 225.86M-31.6% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-84.9%——
1 year+127.8%——
3-year CAGR+7.8%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

SEK · from the cash flow

Latest · FY2025
(375.74M) SEK
Year-over-year change
-127.8%

Operating Cash Flow vs competitors

How VCRE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -31.6% is the lowest of 2, against a peer median of +168.1%.
  • Operating cash flow amounts to 16982.6% of revenue for VCRE, versus a peer median of 17.5%.
VCRE Competitors
Operating Cash Flow for VCRE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VCREVicore Pharma Holding ABLTM Jun 2026SEK 225.86M SEK-31.6%+7.8%16982.6%
LQDALiquidia CorporationLTM Jun 2026$79.03M USD+168.1%+7.7%17.5%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding VCRE) —+168.1%+7.7%17.5%

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.78M)(290.73M)(321.51M)(194.19M)(452.39M)
Depreciation & Amortization397.75K3.61M3.42M2.24M0
Deferred Income Tax00000
Stock-Based Compensation(172.79K)0000
Change in Working Capital(37.59K)(20.94M)(10.65M)(1.84M)40.81M
Accounts Receivables(37.59K)(1.6M)(4.28M)(35.6M)(3.08M)
Inventory00000
Accounts Payables00000
Other Working Capital0(19.34M)(6.36M)33.77M43.89M
Other Non-Cash Items(231.23M)8.13M79.15M28.84M35.84M
Operating Cash Flow(263.82M)(299.92M)(249.58M)(164.95M)(375.74M)
Capital Expenditures0(3M)000
Acquisitions (Net)00000
Purchases of Investments(76.61M)0(199.04M)(64.81M)(983.95M)
Sales of Investments69.64M77M54.58M213.85M383.45M
Other Investing Activities00000
Investing Cash Flow(6.96M)74M(144.46M)149.04M(600.51M)
Debt Repayment00000
Common Stock Issued316.8M200M500.41M882.14M455.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(237.78K)(12.96M)(29.55M)(48.08M)(24.55M)
Financing Cash Flow316.56M187.04M470.86M834.06M430.54M
Effect of Forex Changes(26.64M)1.48M04.23M(32.16M)
Net Change in Cash2.3M(37.4M)76.82M822.38M(577.85M)
Free Cash Flow(263.82M)(302.92M)(249.58M)(164.95M)(375.74M)

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.